Defilade Capital Management L.P. Trims Stock Position in Pfizer Inc. $PFE

Defilade Capital Management L.P. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 33.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,464,129 shares of the biopharmaceutical company’s stock after selling 739,375 shares during the period. Pfizer makes up approximately 5.8% of Defilade Capital Management L.P.’s holdings, making the stock its 4th largest holding. Defilade Capital Management L.P.’s holdings in Pfizer were worth $41,113,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Vanguard Group Inc. boosted its stake in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. KBC Group NV raised its stake in shares of Pfizer by 8.3% during the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock worth $228,924,000 after acquiring an additional 706,426 shares in the last quarter. North Dakota State Investment Board bought a new stake in shares of Pfizer in the 4th quarter worth approximately $5,348,000. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Pfizer in the 4th quarter valued at $76,833,000. Finally, John G Ullman & Associates Inc. grew its holdings in shares of Pfizer by 35.0% during the 4th quarter. John G Ullman & Associates Inc. now owns 206,065 shares of the biopharmaceutical company’s stock valued at $5,131,000 after purchasing an additional 53,467 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4%

NYSE:PFE opened at $25.10 on Monday. The firm has a market capitalization of $143.06 billion, a P/E ratio of 19.16 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average of $25.04 and a 200 day moving average of $26.16. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm earned $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Guggenheim reduced their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.